New pharmacological options for treating advanced parkinson's disease

Clinical Therapeutics

Volumn 35, Issue 10, 2013, Pages 1640-1652

  Devos, David ^a   Moreau, Caroline ^a   Dujardin, Kathy ^a   Cabantchik, Ioav ^b   Defebvre, Luc ^a   Bordet, Regis ^a  

^a UNIV LILLE   (France)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Apathy; Cognition; Dementia; Disease modifying treatment; Gait; Non dopaminergic treatment

Indexed keywords

AMANTADINE; CALCIUM CHANNEL BLOCKING AGENT; CHELATING AGENT; CHOLINESTERASE INHIBITOR; DEFERIPRONE; DIHYDROPYRIDINE; DIZOCILPINE; DOPAMINE TRANSPORTER; ISRADIPINE; LEVODOPA; MEMANTINE; METHYLPHENIDATE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NIFEDIPINE; NORADRENALIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; RASAGILINE; RIVASTIGMINE; ROSIGLITAZONE;

ATTENTION; CHOLINERGIC SYSTEM; CLINICAL TRIAL; CLINICAL TRIAL (TOPIC); COGNITION; COGNITIVE DEFECT; DATA BASE; DEMENTIA; DOPAMINERGIC TRANSMISSION; GAIT DISORDER; HUMAN; IRON OVERLOAD; MEDLINE; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SUBTHALAMIC NUCLEUS;

APATHY; COGNITION; DEMENTIA; DISEASE-MODIFYING TREATMENT; GAIT; NON-DOPAMINERGIC TREATMENT;

APATHY; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS AS TOPIC; DEEP BRAIN STIMULATION; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; DRUG DISCOVERY; GAIT; HUMANS; IRON CHELATING AGENTS; METHYLPHENIDATE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PARKINSON DISEASE; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84885865930     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.08.011     Document Type: Review

References (112)

1. de Lau L., Breteler M. Epidemiology of Parkinson's disease. Lancet Neurol 2006, 5:525-535.
2. Chaudhuri R., Schapira A. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009, 8:464-474.
3. Meissner W.G., Frasier M., Gasser T., et al. Priorities in Parkinson's disease research. Nat Rev Drug Discov 2011, 10:377-393.
4. Olanow C., Stern M., Sethi K. The scientific and clinical basis for the treatment of Parkinson disease. Neurology 2009, 72(Suppl 4):S1-S136.
5. Fox S., Lang A. l-Dopa-related motor complications-phenomenology. Mov Disord 2008, 23(Suppl 3):S509-S514.
6. Factor S. Current status of symptomatic medical therapy in Parkinson's disease. Neurotherapeutics 2008, 5:164-180.
7. Bonuccelli U., Del Dotto P., Rascol O. Role of dopamine receptor agonists in the treatment of early Parkinson's disease. Parkinsonism. Relat Disord 2009, 15:S44-S53.
8. Sethi K. Levodopa unresponsive symptoms in Parkinson disease. Mov Disord 2008, 23(Suppl 3):S521-S533.
9. Krack P., Batir A., Van Blercom N., et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 2003, 349:1925-1934.
10. Drapier S., Gillioz A.S., Leray E., et al. Apomorphine infusion in advanced Parkinson's patients with subthalamic stimulation contraindications. Parkinsonism Relat Disord 2012, 18:40-44.
11. Devos D. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease. Mov Disord 2009, 24:993-1000. French DUODOPA Study Group.
12. Seppi K., Weintraub D., Coelho M., et al. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 2011, 26(Suppl 3):S42-S80.
13. Bloem B.R., Hausdorff J.M., Visser J.E., et al. Falls and freezing of gait in Parkinson's disease: a review of two interconnected, episodic phenomena. Mov Disord 2004, 19:871-884.
14. Aarsland D., Kurz M.W. The epidemiology of dementia associated with Parkinson's disease. Brain Pathol 2010, 20:633-639.
15. Schaafsma J.D., Balash Y., Gurevich T., et al. Characterization of freezing of gait subtypes and the response of each to levodopa in Parkinson's disease. Eur J Neurol 2003, 10:391-398.
16. Nutt J.G., Bloem B.R., Giladi N., et al. Freezing of gait: moving forward on a mysterious clinical phenomenon. Lancet Neurol 2011, 10:734-744.
17. Giladi N. Medical treatment of freezing of gait. Mov Dis 2008, 23:S482-S488.
18. Aarsland D., Andersen K., Larsen J.P., et al. Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology 2001, 56:730-736.
19. Buter T.C., van den Hout A., Matthews F.E., et al. Dementia and survival in Parkinson disease: a 12- year population study. Neurology 2008, 70:1017-1022.
20. Aarsland D., Andersen K., Larsen J.P., et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003, 60:387-392.
21. Hughes T.A., Ross H.F., Musa S., et al. A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease. Neurology 2000, 54:1596-1602.
22. Weintraub S., Mesulam M.M. Four neuropsychological profiles in dementia. Handbook of neuro- psychology 1993, 253-282. Elsevier, Amsterdam. F. Boller, J. Grafman (Eds.).
23. Bronnick K., Emre M., Lane R., et al. Profile of cognitive impairment in dementia associated with Parkinson's disease compared with Alzheimer's disease. J Neurol Neurosurg Psychiatry 2007, 78:1064-1068.
24. Poewe W., Gauthier S., Aarsland D., et al. Diagnosis and management of Parkinson's disease dementia. Int J Clin Pract 2008, 62:1581-1587.
25. Janvin C.C., Larsen J.P., Salmon D.P., et al. Cognitive profiles of individual patients with Parkinson's disease and dementia: comparison with dementia with lewy bodies and Alzheimer's disease. Mov Disord 2006, 21:337-342.
26. Emre M., Aarsland D., Albanese A., et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004, 351:2509-2518.
27. Olin J.T., Aarsland D., Meng X. Rivastigmine in the treatment of dementia associated with Parkinson's disease: effects on activities of daily living. Dement Geriatr Cogn Disord 2010, 29:510-515.
28. Marin R.S. Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci 1991, 3:243-254.
29. Kulisevsky J., Pagonabarraga J., Pascual-Sedano B., et al. Prevalence and correlates of neuropsychiatric symptoms in Parkinson's disease without dementia. Mov Disord 2008, 23:1889-1896.
30. Oguru M., Tachibana H., Toda K., Okuda B., Oka N. Apathy and depression in Parkinson disease. J Geriatr Psychiatry Neurol 2010, 23:35-41.
31. Dujardin K., Sockeel P., Delliaux M., et al. Apathy may herald cognitive decline and dementia in Parkinson's disease. Mov Disord 2009, 24:2391-2397.
32. Dujardin K., Sockeel P., Devos D., et al. Characteristics of apathy in Parkinson's disease. Mov Disord 2007, 22:778-784.
33. Thobois S., Ardouin C., Lhommée E., et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. Brain 2010, 133:1111-1127.
34. Zarow C., Lyness S.A., Mortimer J.A., Chui H.C. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol 2003, 60:337-341.
35. Devos D., Defebvre L., Bordet R. Dopaminergic and non-dopaminergic pharmacological hypotheses for gait disorders in Parkinson's disease. Fundam Clin Pharmacol 2010, 24:407-421.
36. Kalia L.V., Brotchie J.M., Fox S.H. Novel nondopaminergic targets for motor features of Parkinson's disease: review of recent trials. Mov Disord 2013, 28:131-144.
37. Chopin P., Colpaert F.C., Marien M. Effects of alpha-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway. J Pharmacol Exp Ther 1999, 288:798-804.
38. Maertens de Noordhout A., Pepin J.L., Delwaide P.J. Open study of tinazidine in the treatment of freezing gait. 11th International Symposium on Parkinson's disease; Mar 26-30, 1994; Rome, Italy.
39. Ogawa N., Yamamoto M., L-threo-3 Takayama H. 4-dihydroxyphenylserine treatment of Parkinson's disease. J Med 1985, 16:525-534.
40. Narabayashi H., Yokochi F., Ogawa T., Igakura T. Analysis of L-threo-3, 4-dihydroxyphenylserine effect on motor and psychological symptoms in Parkinson's disease. No To Shinkei 1991, 43:263-268.
41. Tohgi H., Abe T., Takahashi S. The effects of L-threo-3,4-dihydroxyphenylserine on the total norepinephrine and dopamine concentrations in the cerebrospinal fluid and freezing gait in parkinsonian patients. J Neural Transm Park Dis Dement Sect 1993, 5:27-34.
42. Kuczenski R., Segal D.S. Effects of methylphenidate on extracellular dopamine, serotonin and norépinephrine comparison with amphétamine. J Neurochem 1997, 68:2032-2037.
43. Volkow N.D., Wang G.J., Fowler J.S., et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 1998, 155:1325-1331.
44. Nutt J.G., Carter J.H., Sexton G.J. The dopamine transporter: importance in Parkinson's disease. Ann Neurol 2004, 55:766-773.
45. Gainetdinov R.R., Jones S.R., Fumagalli F., Wightman R.M., Caron M.G. Re-evaluation of the role of the dopamine transporter in dopamine system homeostasis. Brain Res Brain Res Rev 1998, 26:148-153.
46. Volkow N.D., Wang G., Fowler J.S., et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci 2001, 21. RC 121.
47. Halliday A.M., Dwivedi A.K., Payne M., et al. Methylphenidate in Parkinsonism. BMJ 1961, i:1652-1655.
48. Auriel E., Hausdorff J.M., Giladi N. Methylphenidatefor the treatment ofParkinson diseaseand other neurological disorders. Clin Neuropharmacol 2009, 32:75-81.
49. Pollak L., Dobronevsky Y., Prohorov T., et al. Low dose methylphenidate improves freezing in advancedParkinson's diseaseduring off-state. J Neural Transm Suppl 2007, 72:145-148.
50. Devos D., Krystkowiak P., Clement F., et al. Improvement of gait by chronic, high doses of methylphenidate in patients with advancedParkinson's disease. J Neurol Neurosurg Psychiatry 2007, 78:470-475.
51. Espay A.J., Dwivedi A.K., Payne M., et al. Methylphenidate for gait impairment in Parkinson's disaese: a randomized clinical trial. Neurology 2011, 76:1256-1262.
52. Moreau C., Delval A., Defebvre L., et al. Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial. Lancet Neurol 2012, 11:589-596.
53. Czernecki V., Schüpbach M., Yaici S., et al. Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom. Mov Disord 2008, 23:964-969.
54. Thobois S., Lhommée E., Klinger H., et al. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain 2013, 136:1568-1577.
55. Chatterjee A., Fahn S. Methylphenidatetreats apathy inParkinson'sdisease. J Neuropsychiatry Clin Neurosci 2002, 14:461-462.
56. Camicioli R., Lea E., Nutt J.G., et al. Methylphennidate increases the motor effects of L-Dopa in PD: a pilot study. Clin Neuropharmacol 2001, 24:208-213.
57. Aagaard L., Hansen E.H. The occurrence of adverse drug reactions reported for attention deficit hyperactivity disorder (ADHD) medications in the pediatric population: a qualitative review of empirical studies. Neuropsichiatr Dis Treat 2011, 7:729-744.
58. Savill N., Bushe C.J. A systematic review of the safety information contained within the Summaries of Product Characteristics of medications licensed in the United Kingdom for Attention Deficit Hyperactivity Disorder. how does the safety prescribing advice compare with national guidance?. Child Adolesc Psychiatry Ment Health 2012, 6:2.
59. Attention Deficit Hyperactivity Disorder. Diagnosis and management of ADHD in children, young people and adults: NICE Clinical Guideline 72.2008.
60. Rolinski M., Fox C., Maidment I., McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev 2012, 3. CD006504.
61. Aarsland D., Laake K., Larsen J.P., Janvin C. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002, 72:708-712.
62. Ravina B., Putt M., Siderowf A., et al. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 2005, 76:934-939.
63. Dubois et al. 2007 Donepezil trialremains unpublished.
64. Leroi I., Brandt J., Reich S.G. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry 2004, 19:1-8.
65. Wise R.A. Dopamine, learning and motivation. Nat Rev Neurosci 2004, 5:483-594.
66. Cummings J.L., Back C. The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease. Am J Geriatr Psychiatry 1998, 6:S64-S78.
67. Cummings J.L. Toward a molecular neuropsychiatry of neurodegenerative diseases. Ann Neurol 2003, 54:147-154.
68. Devos D, Moreau C, Maltete D, et al. Rivastigmine in apathetic but dementia-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomized clinical trial. Publication in progress.
69. Chung K.A., Lobb B.M., Nutt J.G., et al. Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease. Neurology 2010, 75:1263-1269.
70. Elahi B., Phielipp N., Chen R. N-Methyl-D-Aspartate antagonists in levodopa induced dyskinesia: a meta-analysis. Can J Neurol Sci 2012, 39:465-472.
71. Stocchi F., Rascol O., Destee A., et al. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Mov Disord 2013 Jul 12, [Epub ahead of print].
72. Svenningsson P., Westman E., Ballard C., Aarsland D. Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment. Lancet Neurol 2012, 11:697-707.
73. Aarsland D., Ballard C., Walker Z., et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2009, 8:613-618.
74. Emre M., Tsolaki M., Bonuccelli U., et al. 11018 Study Investigators. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010, 9:969-977.
75. Rodriguez M.C., Obeso J.A., Olanow C.W. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann Neurol 1998, 44(Suppl 1):S175-S188.
76. Carroll C.B., Holloway V., Brotchie J.M., et al. Neurochemical and behavioural investigations of the NMDA receptor-associated glycine site in the rat striatum: functional implications for treatment of parkinsonian symptoms. Psychopharmacology (Berl) 1995, 119:55-65.
77. Pahapill P.A., Lozano A.M. The pedunculopontine nucleus and Parkinson's disease. Brain 2000, 123:1767-1783.
78. Steiniger B., Kretschmer B.D. Effects of ibotenate pedunculopontine tegmental nucleus lesions on exploratory behaviour in the open field. Behav Brain Res 2004, 151:17-23.
79. Kucheryanu V.G., Kryzhanovskii G.N. Effect of glutamate and antagonists of N-methyl-D-aspartate receptors on experimental parkinsonian syndrome in rats. Bull Exp Biol Med 2000, 130:629-632.
80. Skuza G., Rogoz Z., Quack G., et al. Memantine, amantadine, and L-deprenyl potentiate the action of L-dopa in monoamine-depleted rats. J Neural Transm Gen Sect 1994, 98:57-67.
81. Moreau C., Delval A., Tiffreau V., et al. Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study. J Neurol Neurosurg Psychiatry 2013, 84:552-555.
82. Kim Y.E., Yun J.Y., Yang H.J., et al. Intravenous amantadine for freezing of gait resistant to dopaminergic therapy: a randomized, double-blind, placebo-controlled, cross-over clinical trial. PLoS One 2012, 7:e48890.
83. Fischer P.A., Jacobi P., Schneider E., Schönberger B. Effects of intravenous administration of memantine in parkinsonian patients [in German]. Arzneimittelforschung 1977, 27:1487-1489.
84. Schneider E., Fischer P.A., Clemens R., et al. Effects of oral memantine administration on Parkinson symptoms. Results of a placebo-controlled multicenter study [in German]. Dtsch Med Wochenschr 1984, 109:987-990.
85. Rabey J.M., Nissipeanu P., Korczyn A.D. Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease. J Neural Transm Park Dis Dement Sect 1992, 4:277-282.
86. Merello M., Nouzeilles M.I., Cammarota A., et al. Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study. Clin Neuropharmacol 1999, 22:273-276.
87. Olanow C.W., Rascol O., Hauser R., et al. A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease. N Engl J Med 2009, 361:1268-1278.
88. Rascol O., Fitzer-Attas C.J., Hauser R., et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol 2011, 10:415-423.
89. Schapira A.H., McDermott M.P., Barone P., et al. Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. Lancet Neurol 2013, 12:747-755.
90. Guzman J.N., Sanchez-Padilla J., Wokosin D., et al. Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature 2010, 468:696-700.
91. Rees K., Stowe R., Patel S., Ives N., Breen K., Ben-Shlomo Y., Clarke C.E. Anti-hypertensive drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies and clinical trials. Cochrane Database Syst Rev 2011, 11. CD008535.
92. Marras C., Gruneir A., Rochon P., et al. Dihydropyridine calcium channel blockers and the progression of parkinsonism. Ann Neurol 2012, 71:362-369.
93. Chaturvedi R.K., Beal M.F. PPAR: a therapeutic target in Parkinson's disease. J Neurochem 2008, 106:506-518.
94. Mutez E., Duhamel A., Defebvre L., et al. Lipid-lowering drugs are associated with delayed onset and slower course of Parkinson's disease. Pharmacol Res 2009, 60:41-45.
95. Gao X., Simon K.C., Schwarzschild M.A., Ascherio A. Prospective study of statin use and risk of Parkinson disease. Arch Neurol 2012, 69:380-384.
96. Laloux C., Petrault M., Lecointe C., et al. Differential susceptibility to the PPAR-γ agonist pioglitazone in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine rodent models of Parkinson's disease. Pharmacol Res 2012, 65:514-522.
97. Martin H.L., Mounsey R.B., Mustafa S., et al. Pharmacological manipulation of peroxisome proliferator-activated receptor γ (PPARγ) reveals a role for anti-oxidant protection in a model of Parkinson's disease. Exp Neurol 2012, 235:528-538.
98. Carta A.R., Pisanu A., Carboni E. Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy?. Parkinsons Dis 2011, 2011:689181.
99. Andrews N.C. Disorders of iron metabolism. N Engl J Med 1999, 341:1986-1995.
100. Rouault T.A. Iron metabolism in the CNS: implications for neurodegenerative diseases. Nature (Reviews in Neuroscience) 2013, 14:551-564.
101. Ganz T., Nemeth E. Iron metabolism: interactions with normal and disordered erythropoiesis. Cold Spring Harb Perspect Med 2012, 2:a011668.
102. Duyn J.H. Study of brain anatomy with high-field MRI: recent progress. Magn. Reson Imaging 2010, 28:1210-1215.
103. Gröger A., Berg D. Does structural neuroimaging reveal a disturbance of iron metabolism in Parkinson's disease? Implications from MRI and TCS studies. J Neural Transm 2012, 119:1523-1528.
104. Dexter D.T., Wells F.R., Agid F., et al. Increased nigral iron content in postmortem parkinsonian brain. Lancet 1987, 2:1219-1220.
105. Youdim M.B., Ben-Shachar D., Riederer P. The possible role of iron in the etiopathology of Parkinson's disease. Mov Disord 1993, 8:1-12.
106. Hirsch E.C. Iron transport in Parkinson's disease. Parkinsonism Relat Disord 2009, 15(Suppl 3):S209-S211.
107. Schapira A.H. Targeting mitochondria for neuroprotection in Parkinson's disease. Antioxid Redox Signal 2012, 16:965-973.
108. Andersen J.K. Oxidative stress in neurodegeneration: cause or consequence?. Nat Med 2004, 10(Suppl):S18-S25.
109. Napolitano A., Manini P., d'Ischia M. Oxidation chemistry of catecholamines and neuronal degeneration: an update. Curr Med Chem 2011, 18:1832-1845.
110. Chen B.T., Avshalumov M.V., Rice M.E. Modulation of somatodendritic dopamine release by endogenous H(2)O(2): susceptibility in substantia nigra but resistance in VTA. J Neurophysiol 2002, 87:1155-1158.
111. Boddaert N., Le Quan Sang K.H., Rötig A., et al. Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 2007, 110:401-408.
112. Moreau C., Devedjian J.C., Kluza J., et al. Targeting brain chelatable iron as a therapeutic strategy for parkinson's disease. Translational and clinical studies. Am J Hematol 2013, 88:E5-E243.